A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma Meeting Abstract

  

Authors:	Nghiemphu, P. L.; Omuro, A. M.; Cloughesy, T.; Mellinghoff, I. K.; Norden, A. G.; Nguyen, L. T.; Rajangam, K.; Wen, P. Y.
Abstract Title:	A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma
Meeting Title:	46th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	28
Issue:	15 Suppl.
Meeting Dates:	2010 Jun 4-8
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2010-05-20
Start Page:	254s
Language:	English
ACCESSION:	WOS:000208852003290
PROVIDER:	wos
DOI:	10.1200/jco.2010.28.15_suppl.3085
Notes:	Meeting Abstract: 3085 -- S -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/129532